General Information of Drug Inactive Ingredient (DIG) (ID: E00461)

DIG Name
Hyaluronate sodium
Synonyms
Healon; Hyaluronate Sodium; Hyaluronan; Kopuron; Hyalgan; Hyalurone sodium; Equron (Veterinary); Synacid (veterinary); Arthrease; Cystistat; Hyalart; Hyalein; Hyalovet; Hyladerm; Khionat; Monovisc; Nidelon; Orthovisc; Ostenil; Provisc; Sinovial; Supartz; Suvenyl; Hyasol; Hyladerm Khionat; Nrd101; Hyaluronsan HA-LQ; sodium;(2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid; Bio Hyaluro 12; EUFLEXXA injection; EUFLEXXA; CCRIS 4127; Hyaluronate Sodium [USAN:JAN]; Sodium hyaluronate HMW; UNII-YSE9PPT4TH; SI-4402; SL-1010; Synacid; Equron; Chlamyhyaluronic acid sodium salt; SL 1010; Hyalauronic Acid 99%; YSE9PPT4TH; GTPL4954; Sodium Hyaluronate (Food Grade); EBD4181; Sodium Hyaluronate (Cosmetic Grade); AKOS015896610; Sodium Hyaluronate, Low Molecular Weight; Sodium Hyaluronate, High Molecular Weight; Q27078001; Hyaluronic acid sodium salt; Chlamyhyaluronic acid sodium salt; (3S,4R,5R,6R)-3-[(2S,3R,5S,6R)-3-acetamido-4-[(2S,3R,4S,6S)-6-carboxy-3,4,5-trihydroxy-tetrahydropyran-2-yl]oxy-5-hydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]oxy-6-[(3R,4R,5S,6R)-3-acetamido-2,5-dih; sodium (2S,3S,4R,5R,6R)-3-{[(2S,3R,4R,5S,6R)-4-{[(2R,3R,4S,5S,6S)-6-carboxy-3,4,5-trihydroxyoxan-2-yl]oxy}-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-6-{[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy}-4,5-dihydroxyoxane-2-carboxylic acid
DIG Function
Humectant; Lubricant; Modified-release agent
Formula
C28H44N2NaO23+
Canonical SMILES
CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1O)CO)O)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)C(=O)O)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)C(=O)O)O)O)O)NC(=O)C)O)O.[Na+]
InChI
1S/C28H44N2O23.Na/c1-5(33)29-9-18(11(35)7(3-31)47-25(9)46)49-28-17(41)15(39)20(22(53-28)24(44)45)51-26-10(30-6(2)34)19(12(36)8(4-32)48-26)50-27-16(40)13(37)14(38)21(52-27)23(42)43;/h7-22,25-28,31-32,35-41,46H,3-4H2,1-2H3,(H,29,33)(H,30,34)(H,42,43)(H,44,45);/q;+1/t7-,8-,9-,10-,11-,12-,13+,14+,15-,16-,17-,18-,19-,20+,21+,22+,25-,26+,27-,28-;/m1./s1
InChIKey
YWIVKILSMZOHHF-QJZPQSOGSA-N
Physicochemical Properties Molecular Weight 799.6 Topological Polar Surface Area 400
XlogP N.A. Complexity 1300
Heavy Atom Count 54 Rotatable Bond Count 12
Hydrogen Bond Donor Count 14 Hydrogen Bond Acceptor Count 23

Full List of Drug(s) Co-administrated with This DIG

1 Approved Drug(s) Co-administrated with This DIG
Drug Name Drug ID Indication Formulation Name Formulation ID
Adenosine DMM2NSK Paroxysmal supraventricular tachycardia [BC81.Z] Adenosine 0.04% cream F23604
------------------